Precise Medical Cannabis
Cultivated by Science

Breeding tomorrow's Cannabis products with state of the art technologies
Part of the Evogene group, a global powerhouse in plant innovation, Canonic features Israel's largest Cannabis R&D facilities, greenhouses and labs – all synchronized with our Computational Predictive Biology platforms to advance
the therapeutic efficacy of our products.
Developing two product families
featured by accurate Genetic Makeup
MetaYield
MetaYield significantly enhances total active
compounds per plant and area, for higher
profitability and lower cost to end user.
Precise
Precise significantly enhances specific active
compounds based on medical indication and
compound profile, for increased therapeutic effect.
Targeting a wide range of
medical indications
Starting with inflammation and pain
Our Cannabis varieties are developed hand in hand with pre-clinical
trials in collaboration with Hadassah Medical Center, supporting the
development of first of their kind anti-inflammatory medical products.
Future applications include chronic pain, cancer and more.
Harnessing AI to enhance therapeutic efficacy in
tailor-made products
Combining advanced breeding approaches with unrivaled
artificial intelligence (AI) and big data, Canonic maps and decodes the Cannabis genome, identifying unique genetic markers that enhance desired traits or specific active compounds.
Newsroom
Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products
Read More
Canonic Announces Signing of First Cultivation Agreement for its Medical Cannabis Varieties
Read More
Canonic Received Approval for Propagation of Medical Cannabis from the Israel Medical Cannabis Agency
Read More
Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products
Read More
Canonic Announces an Agreement with Hadassah Medical Center for Pre-Clinical Studies to Support the Development of Canonic’s Medical Cannabis Products
Read More
Evogene to Develop Next Generation Medical Cannabis Products through New Subsidiary – Canonic Ltd
Read More
We use cookies

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.